DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Inotuzumab ozogamicin is an investigational drug.
There have been 33 clinical trials for Inotuzumab ozogamicin. The most recent clinical trial was a Phase 2 trial, which was initiated on February 26th 2019.
The most common disease conditions in clinical trials are Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, and Leukemia. The leading clinical trial sponsors are Pfizer, UCB Pharma, and M.D. Anderson Cancer Center.
There are fifteen US patents protecting this investigational drug and two hundred and forty-two international patents.
Recent Clinical Trials for Inotuzumab ozogamicin
|Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy||National Cancer Institute (NCI)||Phase 3|
|Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy||Children's Oncology Group||Phase 3|
|Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia||National Cancer Institute (NCI)||Phase 1|
Top disease conditions for Inotuzumab ozogamicin
Top clinical trial sponsors for Inotuzumab ozogamicin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Inotuzumab ozogamicin||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Inotuzumab ozogamicin||Start Trial||Combination therapy with glutaminase inhibitors and immuno-oncology agents||Calithera Biosciences, Inc. (South San Francisco, CA)||Start Trial|
|Inotuzumab ozogamicin||Start Trial||Stabilizing alkylglycoside compositions and methods thereof||Aegis Therapeutics LLC (San Diego, CA)||Start Trial|
|Inotuzumab ozogamicin||Start Trial||Processes for making hydrazides||Wyeth LLC (Madison, NJ)||Start Trial|
|Inotuzumab ozogamicin||Start Trial||P97 fragments with transfer activity||biOasis Technologies, Inc. (Vancouver, British Columbia, unknown)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Inotuzumab ozogamicin||Australia||2013220749||2032-02-15||Start Trial|
|Inotuzumab ozogamicin||Brazil||112014019627||2032-02-15||Start Trial|
|Inotuzumab ozogamicin||Canada||2862476||2032-02-15||Start Trial|
|Inotuzumab ozogamicin||China||104114705||2032-02-15||Start Trial|
|Inotuzumab ozogamicin||China||108570468||2032-02-15||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|